Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30138564 | 1.00 | SLC6A2 (0.32) | SLC6A2SLC6A3 | |
| SCHEMBL9251530 | 0.72 | LMNA (0.31) | — | |
| SCHEMBL11383230 | 0.70 | LMNA (0.36) | — | |
| SCHEMBL10371759 | 0.68 | CES2 (0.33) | — | |
| SCHEMBL11104413 | 0.67 | HPGD (0.33) | SLC6A2SLC6A3 | |
| SCHEMBL16446965 | 0.67 | HPGD (0.33) | SLC6A2SLC6A3 | |
| SCHEMBL1799677 | 0.67 | HPGD (0.33) | SLC6A2SLC6A3 | |
| SCHEMBL8718896 | 0.67 | HPGD (0.34) | — | |
| SCHEMBL6142770 | 0.67 | HPGD (0.33) | SLC6A2SLC6A3 | |
| SCHEMBL9614440 | 0.67 | HPGD (0.33) | SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230201239-A1 | ALKYNYL NUCLEOSIDE ANALOGS FOR TREATMENT OF HEPATITIS E | Janssen Pharmaceuticals, Inc. | 2023-06-29 | — | — | US | disclosed |
| US-8278282-B2 | Nucleoside analogs for treatment of viral infections | NOVARTIS AG (CH) | 2012-10-02 | — | — | US | disclosed |
| EP-2132216-B1 | NOVEL NUCLEOSIDE ANALOGS FOR TREATMENT OF VIRAL INFECTIONS | NOVARTIS PHARMA AG (CH) | 2011-11-16 | — | — | EP | disclosed |
| WO-2011131167-A2 | BISTABLE MAGNETIC ACTUATOR | JOHNSON ELECTRIC DRESDEN GMBH (DE) | 2011-10-27 | — | — | WO | disclosed |
| US-20100227833-A1 | NOVEL NUCLEOSIDE ANALOGS FOR TREATMENT OF VIRAL INFECTIONS | NOVARTIS PHARMA AG (CH) | 2010-09-09 | — | — | US | disclosed |
| US-20100144655-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-06-10 | — | — | US | disclosed |
| WO-2010015643-A1 | NEW ANTIVIRAL MODIFIED NUCLEOSIDES | NOVARTIS AG (CH) | 2010-02-11 | — | — | WO | disclosed |
| WO-2010015637-A1 | NEW ANTIVIRAL MODIFIED NUCLEOSIDES | NOVARTIS AG (CH) | 2010-02-11 | — | — | WO | disclosed |
| EP-2132216-A1 | NOVEL NUCLEOSIDE ANALOGS FOR TREATMENT OF VIRAL INFECTIONS | Novartis Pharma AG. (CH) | 2009-12-16 | — | — | EP | disclosed |
| WO-2008095993-A1 | NOVEL NUCLEOSIDE ANALOGS FOR TREATMENT OF VIRAL INFECTIONS | NOVARTIS AG (CH) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230201239-A1 | ALKYNYL NUCLEOSIDE ANALOGS FOR TREATMENT OF HEPATITIS E | HAVCR2, PNP, ENTPD5 | SLC6A2 2238/4885SLC6A3 2518/4885 |
| US-20100227833-A1 | NOVEL NUCLEOSIDE ANALOGS FOR TREATMENT OF VIRAL INFECTIONS | MAVS, HAVCR2, SAMHD1 | SLC6A2 1920/4885SLC6A3 2377/4885 |
| US-20100144655-A1 | ORGANIC COMPOUNDS | OAT, MAVS, HAVCR2 | SLC6A2 2956/4885SLC6A3 3003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.